Eli Lilly stock (LLY) slips as Ventyx deal, Zepbound arthritis data and TuneLab AI tie-up come into view
New York, Jan 9, 2026, 11:27 EST — Regular trading Eli Lilly and Company (LLY) shares were down about 0.4% at $1,081 in morning trade on Friday. The drugmaker said this week it will buy autoimmune developer Ventyx Biosciences for $1.2 billion in cash, bringing oral candidates for inflammatory bowel disease into its pipeline. The $14-a-share offer is slated to close in the first half of 2026, and Cantor Fitzgerald analyst Carter Gould described the price as “borderline immaterial” for Lilly. (Reuters) Lilly’s stock has been trading on the next act as much as the drugs it’s selling today. With